Because G100 enhanced the therapeutic efficacy of ZVex-induced T cells via inflammation of the TME resulting in increased trafficking of ZVex-induced tumor-specific CD8 T cells, we hypothesized that G100 could also combine synergistically with ACT via a similar mechanism. This evidence concerns the gene CD8A and neoplasm.